DOI: 10.1055/s-00050348

Indian Journal of Medical and Paediatric Oncology

References

Zandberg DP, Algazi AP, Jimeno A. et al.
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.

Eur J Cancer 2019;
107 (107) 142-152

Download Bibliographical Data

Access:
Access: